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Non-standard abbreviations 
ARNT Aryl hydrocarbon nuclear translocator 
CPT Carnitine palmitoyltransferase 
GLUT Glucose transporter 
HIF Hypoxia inducible factor 
MCAD medium-chain acyl-CoA dehydrogenase 
MRI Magnetic resonance imaging 
MRS Magnetic resonance spectroscopy 
PCr Phosphocreatine 
PDK pyruvate dehydrogenase kinase 
PPAR Peroxisome proliferator-activated receptor 
PHD prolyl hydroxylase domain 
UCP Uncoupling protein 
VHL von Hippel-Lindau 
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Abstract 
The role of peroxisome proliferator activated alpha (PPARα) -mediated metabolic remodeling in cardiac 
adaptation to hypoxia has yet to be defined.  Here, mice were housed in hypoxia for 3 weeks before in vivo 
contractile function was measured using cine magnetic resonance (MR) imaging.  In isolated, perfused hearts, 
energetics were measured using 
31
P MR spectroscopy and glycolysis and fatty acid oxidation were measured 
using 
3
H labelling.  Compared with normoxic, chow-fed control mouse heart, hypoxia decreased PPARα 
expression, fatty acid oxidation and mitochondrial UCP3 levels, while increasing glycolysis, all of which served 
to maintain normal ATP concentrations and thereby ejection fractions.  A high-fat diet increased cardiac PPARα 
expression, fatty acid oxidation and UCP3 levels, with decreased glycolysis.  Hypoxia was unable to alter the 
high PPARα expression or reverse the metabolic changes caused by the high fat diet, with the result that ATP 
concentrations and contractile function decreased significantly.  The adaptive metabolic changes caused by 
hypoxia in control mouse hearts were found to have already occurred in PPARα-/- mouse hearts, and sustained 
function in hypoxia despite an inability for further metabolic remodelling.  We conclude that decreased cardiac 
PPARα expression is essential for adaptive metabolic remodelling in hypoxia, but is prevented by dietary fat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Cardiac contractile function; Cine magnetic resonance imaging; Hypoxia inducible factor (HIF); 
Myocardial energy metabolism; 
31
P Magnetic resonance spectroscopy; Substrate metabolism 
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Introduction 
Each day, the human heart beats about 100,000 times and pumps about 10 tons of blood through the body, so 
requiring around 6 kg of ATP.(1)  To produce such a large quantity of ATP, the heart relies on mitochondrial 
oxidative phosphorylation of a variety of metabolic fuels, including free fatty acids (FFA) and glucose.  In 
theory, FFAs require ~13% more oxygen than glucose to generate the same amount of ATP, although hearts 
metabolising FFAs may require far more oxygen owing to increased mitochondrial uncoupling.(2, 3)  ATP is 
transported from the mitochondria to be used for contractile function via the creatine kinase energy shuttle, in 
which phosphate is transferred from ATP to creatine with the formation of phosphocreatine and ADP, in a 
reaction catalysed by mitochondrial creatine kinase:(1) 
 
ATP + Cr ↔ PCr + ADP + H+ 
 
The creatine kinase system acts to keep ATP levels constant via a fall in phosphocreatine and a rise in free ADP, 
which controls mitochondrial oxidative phosphorylation when oxygen is not limiting.(4)  
In hypoxia, when oxygen availability limits oxidative phosphorylation, the heart moves towards more oxygen-
efficient carbohydrate, away from fatty acid metabolism.(5)  Thus, cardiac glucose uptake was increased in 
hypoxic rats(6) and in high altitude-adapted humans(7), and fatty acid metabolising enzyme (carnitine 
palmitoyltransferase 1 (CPT1) and medium-chain acyl-CoA dehydrogenase (MCAD)), expression was decreased 
by hypoxia.(8-10)  Magnetic resonance (MR) studies have shown that cardiac PCr/ATP ratios are lower in high 
altitude-adapted humans(11) and in lowlanders returning to sea level following a trek to Mt Everest Base 
Camp.(12)  However, the links between limited oxygen availability, changes in substrate metabolism, ATP 
generation and cardiac function have not been well defined.  
The balance between fatty acid and glucose metabolism may be regulated, at least in part, by the nuclear 
peroxisome proliferator activated receptors (PPARs).  Of the three receptor isoforms, α, δ and Ȗ, PPARα and 
PPARδ are highly expressed in heart.(13)  PPARα regulates several genes encoding for proteins that control 
fatty acid metabolism, including MCAD,(14) and glucose metabolism, including pyruvate dehydrogenase kinase 
4 (PDK4) and GLUT4.(15) 
 
Hypoxia is a potential driver of metabolic reprogramming, with the oxygen-sensitive transcriptional activator, 
hypoxia-inducible factor 1α (HIF-1α), being elevated in ischemic cardiac myocytes(16) and in infarcted 
hearts.(17)  In normoxia, HIFα subunits are polyubiquitinated for proteasomal degradation, the constant 
degradation of HIFα subunits being mediated by hydroxylation via the prolyl hydroxylase domain (PHD or 
EGLN) oxygenase family.  In hypoxia, PHD activity is reduced, stabilizing HIFα, which translocates to the 
nucleus and dimerizes with HIF1.  The dimer transcriptionally activates ~200 genes, including those involved 
in erythropoiesis, angiogenesis and energy metabolism.(18)  In hypoxia-adapted Tibetans, variants of the genes 
EGLN1 and EPAS1, encoding for PHD2 (the most important of the three human PHDs) and the HIF-2α subunit, 
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respectively, associated with the PPARA gene in genome-wide scans,(19) and serum fatty acid concentrations in 
this group correlated with the PPARA haplotype.(20)  These findings suggest that PPARα may control cardiac 
substrate metabolism, ATP generation and thereby cardiac function in hypoxia (Figure 1). 
 
Recent studies using cultured cells, knockout or transgenic mice seemingly demonstrate that alterations in the 
HIF system, whether decreases or increases in ARNT (HIF1)(21), HIF1, HIF2, PHD1(25), 
or VHL(26) levels, increase either PPAR or PPAR(22) in heart or skeletal muscle.  Such apparently 
contradictory studies necessitate a deeper understanding of the cellular mechanisms whereby a decrease in 
PPAR is absolutely required to maintain ATP levels for the contractile function of the hypoxic heart.  Here, we 
show that hypoxia causes the heart to undergo a series of metabolic changes, coordinated by PPAR and 
designed to use the limited available oxygen as efficiently as possible.  We demonstrate in normal mice how a 
high fat diet increases PPAR expression, which prevents the metabolic changes required for acclimation to 
hypoxia, thereby significantly decreasing ATP concentrations and myocardial contractile function.  We also 
demonstrate that the lack of myocardial PPAR prevents any metabolic response to hypoxia and that chemical 
induction of HIF, by inhibition of HIF hydroxylases in mechanically active cardiomyocytes, has the same effect 
on PPAR as hypoxia.  In short, for adaptation to hypoxia, it is essential that PPARα expression decreases in 
order to increase the efficiency of oxygen use, via orchestrated changes in substrate metabolism and 
mitochondrial respiration, so that normoxic ATP concentrations and cardiac function can be maintained. 
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Methods 
Animals 
Male wild-type 129Ev/Sv (n = 106, 14 mo) and littermate PPARα-/- mice (n = 72) were housed on a 12 h 
light/dark cycle and fed ad libitum.  The mice, a kind gift from Dr Frank J. Gonzalez (National Cancer Institute, 
Bethesda, MD, USA), were bred in-house on a pure 129Ev/Sv background with 10 backcrosses.  All procedures 
conformed to ethical regulations of the UK Home Office. 
 
Hypoxia 
Mice were housed in a glass-fronted hypoxia chamber (Biospherix, USA) in which N2 replaced O2.  Chamber 
O2, monitored continuously, was used to regulate chamber N2 levels via a feedback system.  Mice were fed 
laboratory chow (7.5% fat) or a high fat (55% fat) diet.  In order to acclimatize mice to hypoxia, chamber O2 was 
reduced in daily steps over a 7 day period, to be maintained at 11% (v:v) for a further 12 days.  Following 
hypoxia, animals were re-oxygenated for 1 h to ameliorate any short term effects of re-oxygenation on cardiac 
function. 
 
Cardiac magnetic resonance imaging 
Magnetic resonance imaging (MRI) was carried out on an 11.7T (500 MHz) vertical bore (123 mmø) magnet 
(Magnex Scientific, Oxon, UK) as described previously.(27) 
 
Heart perfusion 
Mice were anesthetised using 60 mg.kgbw-1 i.p. sodium pentobarbitone and hearts were excised and arrested in 
ice-cold Krebs-Henseleit buffer.  Hearts were perfused in Langendorff mode at 80 mmHg perfusion pressure and 
at 37 ºC with modified Krebs-Henseleit recirculating buffer gassed with 95% O2/5% CO2 containing 11 mM 
glucose and 0.4 mM palmitate pre-bound to 1.5% (w:v) albumin.  A polyethylene balloon connected to a 
pressure transducer was inserted in the left ventricle and inflated to an end-diastolic pressure of 4-8 mmHg to 
measure pressures and heart rates. 
 
Cardiac substrate metabolism 
Glycolytic flux and palmitate oxidation were measured in perfused hearts using 25 µCi [5-
3
H]-glucose or [9,10-
3H]-palmitate, respectively, in recirculating perfusion buffer, as previously described.(3, 28)  Buffer samples 
were taken every 5 min for the measurement of [
3
H] label conversion to 
3
H2O using Dowex anion separation or 
Folch extraction.  In a subset of experiments, insulin (500 μU) was added to the buffer to measure maximal 
insulin-stimulated response.  Hearts were snap-frozen in liquid N2.  Cardiac lactate efflux was determined by 
measuring lactate concentrations, using lactate dehydrogenase, in timed buffer collections. 
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Cardiac high energy phosphate metabolism 
Perfused hearts were inserted into the same NMR system as used for imaging (see above), but using a 10 mm 
diameter probe (Rapid, Wolfsburg, Germany).  
31
P MR spectra were collected using a 60 µs pulse, TR 10 s and 
60 averages in a total acquisition time of 5 min.  Data were analysed using jMRUI software and 4 spectra were 
summed to determine ATP, PCr and Pi peak areas.  Intracellular pH, cytosolic free ADP, and the free energy of 
ATP hydrolysis, ΔGATP, were calculated as previously described.(4) 
 
HL-1 cardiomyocyte culture 
HL-1 murine cardiomyocytes, a kind gift from Dr William C. Claycomb (Louisiana State University Medical 
Center, New Orleans, LA, USA), were maintained in Claycomb medium (Sigma, UK).  Cells were 
supplemented with 10% fetal bovine serum, ascorbic acid (0.3 mM), norepinephrine (0.1 mM) and L-glutamine 
(4 mM).  Cells were cultured on plates pre-coated with 5 µg.ml
-1
 fibronectin and 0.02% gelatin and incubated in 
5% CO2 at 37 ºC and 95% humidity.  All experiments were performed on confluent, beating cells.  Cells were 
exposed to 2% hypoxia or normoxia for 24 h.  In separate experiments, normoxic HL-1 cells were incubated for 
24 h with a specific PHD inhibitor, 50 µM 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetic acid, 
IOX3,(29, 30) which was synthesized specifically for the experiment.(31)  Cells were aspirated with PBS and 
harvested for protein analysis or RTqPCR. 
 
RTqPCR analysis of cardiac and skeletal muscle and HL-1 cells 
Primers were designed using Primer3 software based on GenBank or Ensembl Genome Browser searches and 
obtained from Eurofins MWG Operon (UK). References to primer sequences were; PPARα, NM_011144.6; 
PPARȕ/δ, NM_011145.3; PPARȖ, NM_011146.3; MCAD, NM_007382.4; UCP3, NM_009464.3; PDK4, 
NM_013743.2; VEGF, NM_009505.4; ȕ-Actin, NM_007393.3. Total RNA was extracted and purified from 
frozen heart and skeletal muscle tissues using a Qiagen® Kit (UK).  For cells, total RNA was extracted and 
purified from ≤ 5x106 confluent HL-1 cells using a Qiagen® kit (UK).   Complementary DNA (cDNA) was 
synthesized from the RNA template using a high capacity transcriptase kit (Applied Biosystems).  Real time 
PCR amplification was performed using the Applied Biosystems RTqPCR System (CA).  The PCR program had 
an initial heat activation step of 95
º
C for 10min.  Forty cycles of thermocycling were performed with a 
denaturation step at 95
º
C for 15 s, an annealing and extension step at 60 ºC for 1 min.  Fluorescence was 
measured following each extension step. After amplification, a melting curve was acquired and used to 
determine the PCR product specificity.  Relative quantification of target gene expression was normalized to the 
housekeeping gene, ȕ-actin and performed using a 2-∆∆Ct method. 
 
Tissue and cell lysate preparation and immunoblotting 
As previously described,(3, 28) powdered frozen cardiac or skeletal muscle was added to 300 µl of lysis buffer 
and homogenised for 30 s.  Confluent HL-1 cardiomyocytes in 6-well plates were washed with PBS and added 
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to 150 µl of lysis buffer containing protease inhibitor.  Lysates were boiled for 5 min and centrifuged at 13,000 
rpm for 10 min, supernatant was saved and protein concentrations determined using a BCA protein assay kit 
(Perbio, UK).  Samples were stored at -80 ºC following addition of 5% ȕ-mercaptoethanol (v/v) and boiling for 5 
min. 
Equal concentrations of protein from cardiac and skeletal muscle samples were loaded onto 12% SDS-PAGE 
gels, separated using electrophoresis and transferred onto Immobilon-P membranes (Millipore, UK).  Cardiac 
and skeletal muscle proteins were detected using the following polyclonal antibodies and dilutions, in 5% milk; 
PGC1α and MCAD, Santa Cruz, CA, USA, 1:500; GLUT1, Abcam, UK, 1:1000; GLUT4, Kind gift G. Holman, 
Bath, UK, 1:4000; PDK4 and UCP3, Abgent, UK, 1:500 and 1:2500; MTE-1,  Kind gift, Dr S. Alexson, 
Karolinska Institute, Stockholm, Sweden, 1:2000; RXRα, Santa Cruz, UK, 1:1000; HIF-1 and 2α, Novus 
Biologicals, 1:2000 and 1:500. 
Secondary antibodies were horseradish peroxidase
 
conjugate polyclonal with goat anti-rabbit specificity 
(Autogen Bioclear, Wiltshire, UK), all diluted to 1:3500, with the exception of GLUT1,4 and HIF-1α (1:2000), 
HIF-2α (1:1000) and MCAD (Donkey anti-goat).  Consistent protein loading and transfer were confirmed by 
Ponceau staining, and protein levels related to internal standards to ensure homogeneity between samples and 
gels.  Bands were quantified using UN-SCAN-IT software (Silk Scientific, USA), and all samples run in 
duplicate on separate gels to confirm results. 
 
Glycolytic Enzyme Activities 
The myocardial enzymatic activities of 3-phosphoglycerate kinase (PGK) and pyruvate kinase (PK) were 
measured using coupled enzyme assays.(32)  Frozen, ground heart tissue (1 mg/ml) was extracted with the buffer 
containing 150 mM NaCl, 60 mM Tris-HCl, 5 mM EDTA, 0.2% Triton-X 100, 1 mM PMSF, 10 ug/ml 
leupeptin, 1 ug/ml aprotinin, pH 7.5  The pyruvate kinase activity was assayed at 30 °C, 340 nm in media 
containing 50 mM imidazole (pH 7.6), 20 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 0.1 mM NADH, 1 mM ADP, 
4.5 U/ml lactate dehydrogenase and 1 mM phosphoenolpyruvate. The 3-phosphoglycerate kinase activity was 
recorded at 25 °C, 340 nm in an assay medium containing 50 mM imidazole buffer (pH 7.6), 2 mM MgCl2, 0.1 
mM EDTA, 1 mM ATP, 5 mM 3-phosphoglycerate, and 0.2 mM NADH. 
 
Myocardial triacylglycerol (TAG) assay 
As previously described,(3, 28) cardiac lipids were extracted from freeze-clamped tissue (25-50 mg) using 10 ml 
of 2:1 chloroform:methanol solution.  After mixing and phase separation, the lower phase was air dried at 50
o
C 
and resuspended in ethanol.  Using a kit (RANDOX, UK), cardiac triacylglycerol (TAG) content was measured 
spectrophotometrically at 500 nm. 
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Statistics 
Grouped data (means ± SEM) were analysed using three factor ANOVAs, with individual comparisons 
subsequently performed using t-tests.  Results were considered significantly different at p < 0.05. 
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Results 
Effects of hypoxia on mouse physiology and cardiac morphology 
In order to investigate functional and metabolic responses of the in vivo mouse heart to hypoxia, we used a 3-
week protocol that began with 7 d of lowering ambient oxygen concentration from 21 to 11% in daily 
increments, to produce a graded, physiological hypoxia (Figure 2).  Hypoxia in wild-type, chow-fed mice 
increased whole blood hemoglobin by 51% (p<0.001) and hematocrit by 33% (p<0.001), but did not alter body 
weight.  Established HIF-1α downstream targets, cardiac VEGF and PDK1 protein increased 3.6-fold (p<0.001) 
and 1.8-fold (p<0.01) respectively.  Left ventricular (LV) mass decreased by 19% (p<0.001) following hypoxia, 
whereas right ventricular mass was unaltered.  Plasma metabolites in wild-type mice were unchanged by hypoxia 
(Figure S1). 
 
Effects of hypoxia on cardiac function and metabolism (chow-fed wild-type mice) 
Hypoxia in chow-fed, wild-type mice decreased cardiac PPARα mRNA levels by 36% (p<0.05), with PPARδ 
mRNA, and PPARȖ, RXR and PGC-1α protein levels remaining unchanged (Figures 3A and S2).  In parallel 
with lower PPARα mRNA levels, hypoxia decreased protein levels of downstream targets of PPARα: UCP3, 
MTE-1 and PDK4 (Figure 3B).  MCAD protein levels were 24% (p<0.05) lower, but proteins involved in 
mitochondrial respiration were unchanged, following hypoxia (Figure S2). 
Hypoxia increased cardiac glycolysis 2.3-fold (p<0.01) and lactate efflux 2.4-fold (p<0.01), measured in 
isolated, beating perfused hearts using 
3
H substrate labelling (Figure 3C).  Hypoxia did not alter total cardiac 
glucose transporter-4 (GLUT-4) protein or activities of glycolytic intermediates (Figure S3).  Fatty acid 
oxidation was 26% (p<0.02) lower in hearts from hypoxic mice compared to normoxic controls (Figure 3D), 
whilst myocardial TAG levels were 28% (p<0.05) higher in hypoxic mice.  In isolated, perfused hearts, [PCr] 
was 31% (p<0.001) lower, but [ATP] was unaltered by hypoxia, measured using 
31
P NMR spectroscopy and 
HPLC (Figure 3E); total creatine was 28% (p<0.05) lower following hypoxia.  Although free cytosolic [ADP] 
increased 2-fold (p<0.02), the calculated free energy available from ATP hydrolysis, ΔGATP, was preserved.  In 
vivo cine MRI showed that 3 weeks of hypoxia did not alter cardiac output, cardiac index or ejection fraction, 
despite an 18% (p<0.02) lower stroke volume (SV), resulting from a 17% (p<0.05) lower end-diastolic volume 
(EDV) in hypoxic mice (Figure 3F). 
 
Effect of hypoxia on cardiac function and metabolism in high fat-fed, wild-type mice 
The cardiac metabolic and energetic changes observed in hypoxic mice may have been caused by decreased 
PPARα expression.  To investigate whether PPARα expression is central to hypoxic adaptation, we prevented 
PPARα down-regulation by increasing PPARα expression using high (55%) fat feeding.  Feeding mice a high fat 
diet for 3 weeks in normoxia did not alter body weight, but with hypoxia caused a 10% (p<0.01) loss of body 
weight and a 19% (p<0.01) decrease in LV mass (Table S1).  High fat feeding increased PPARα mRNA 
expression in both normoxia and hypoxia (p<0.05), preventing any hypoxia-induced decrease (Figure 4A).  
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PPARδ mRNA, and PPARȖ, RXR and PGC-1α protein levels were unchanged by high fat feeding.  Downstream 
targets of PPARα, UCP3 and MTE-1 proteins, increased 2-fold (p<0.001), and MCAD protein increased by 39% 
(p<0.01) with high fat feeding under both normoxia and hypoxia (Figures 4B and S2).  High fat feeding did not 
significantly increase cardiac PDK4 protein, although it prevented the decrease caused by hypoxia in chow-fed 
mice.   
High fat feeding prevented the increase in cardiac glycolysis and lactate efflux that occurred in chow-fed mice in 
hypoxia, although it decreased GLUT-4 protein by 59% (p<0.05), which  remained unaltered by hypoxia (Figure 
4C).  High fat feeding increased cardiac fatty acid oxidation by 22% (p<0.05, Figure 4D) and myocardial TAG 
content by 82% (p<0.01), both being unaffected by hypoxia.  High fat feeding decreased cardiac [PCr] by 25% 
(p<0.05) in normoxic mice, but [PCr] did not decrease further with hypoxia (Figure 4E).  [ATP] was normal in 
normoxic high fat-fed mouse hearts, but was 31% (p<0.05) lower in hearts from hypoxic high fat-fed mice 
compared to chow-fed normoxic mice.  Total creatine was unaltered in normoxic high fat-fed hearts, but was 
37% (p<0.05) lower in hearts from high fat-fed mice exposed to hypoxia.  Free cytosolic [ADP] was 55% 
(p<0.05) higher in hearts from normoxic high fat-fed mice compared to normoxic chow-fed mice, and increased 
by a further 38% with hypoxia (p<0.05).  High fat feeding significantly lowered cardiac ΔGATP in all mouse 
hearts. 
High fat feeding under normoxia had no effect on cardiac function (Figure 4F), whereas feeding a high fat diet 
under hypoxia decreased in vivo cardiac output by 24% compared to normoxic chow (p<0.01) or high fat-fed 
(p<0.05) mice.  This was due to a 35% (p<0.001) lower SV, accounted for by a 28% (p<0.01) lower EDV and 
despite a significantly higher heart rate.  The cardiac index was decreased by 15% (p<0.05) and ejection 
fractions were 12% (p<0.02) lower than in normoxic chow-fed mice.  Hence, high fat feeding prevented the 
adaptive molecular and metabolic responses to hypoxia that were observed in chow-fed mouse hearts, thereby 
causing cardiac dysfunction. 
 
Effect of hypoxia on cardiac function and metabolism in PPARα-/-mice 
Having demonstrated that increased PPARα was associated with impaired function of the hypoxic heart, we next 
determined whether loss of PPARα altered cardiac metabolic and functional responses to hypoxia.  PPARα-/- 
mice were fed a chow diet and housed under hypoxia for 3wks.  PPARα-/- mice had 13% (p<0.05) lower body 
weight and 18% (p<0.05) lower LV mass than wild-type mice, with neither altered by hypoxia (Table S1).  
Cardiac PPARα mRNA levels in PPARα-/- mice were negligible, although PPARδ mRNA, and PPARȖ, RXR 
and PGC-1α protein levels were normal and unchanged by hypoxia (Figures 5A and S2).  Cardiac UCP3 protein 
(Figure 5B) was 71% (p<0.001) lower and MTE-1 was 49% (p<0.02) lower in PPARα-/- mouse hearts compared 
with wild-type mice, and both were unchanged by hypoxia. Other key mitochondrial proteins were unaltered 
relative to wild-type mice (Figure S2). PDK4 was 45% lower (p<0.01) and MCAD protein was 43% (p<0.001) 
lower in normoxic and hypoxic PPARα-/- mouse hearts. 
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PPARα-/- mouse hearts had 3-fold (p<0.01) higher glycolytic rates than normoxic wild-type mouse hearts and 
were unaffected by hypoxia (Figure 5C).  Glycolysis was not maximal following hypoxia, as stimulation with 
insulin doubled glycolytic rates in both normoxic and hypoxic PPARα-/- mouse hearts (Figure S4).  Lactate 
efflux from hypoxic PPARα-/- mouse hearts was 2-fold (p<0.01) higher than from normoxic wild-type hearts, 
and not different from normoxic PPARα-/- hearts.  Cardiac GLUT-4 protein was similar in normoxic and hypoxic 
PPARα-/- mice.  Consistent with PPARα being a regulator of fatty acid metabolism, PPARα-/- mice had 24% 
lower (p<0.05) cardiac fatty acid oxidation (Figure 5D) than wild-type mice, and this was unaltered by hypoxia.  
Cardiac TAG content was increased by 45% (p<0.05) in normoxic and hypoxic PPARα-/- mouse hearts.  Thus, 
the lack of PPAR prevented the metabolic changes that were observed in hypoxic wild-type mouse hearts. 
In PPARα-/- mice, [PCr] was decreased by 43% (p<0.001) although [ATP] was unaltered compared to normoxic 
wild-type mouse hearts (Figure 5E).  Hypoxic cardiac [PCr] and [ATP] were decreased by 51% (p<0.001) and 
34% (p<0.05), respectively, in PPARα-/- mice.  Total creatine was decreased by 20% (p<0.001) in PPARα-/- 
mouse hearts, with no effect of hypoxia.  As a consequence, cytosolic free [ADP] was 2.7-fold (p<0.05) higher 
and ΔGATP  significantly lower in all PPARα-/- mouse hearts, being unaltered by hypoxia. 
Normoxic PPARα-/- mice had normal cardiac function, but hypoxic PPARα-/- mice had 23% lower EDV 
(p<0.01), 19% lower ESV (p<0.05), 29% (p<0.01) lower SV and therefore 20% lower cardiac output than 
normoxic wild-type mice (Figure 5F).  Therefore, deletion of PPAR significantly altered myocardial substrate 
and energy metabolism and prevented any metabolic response to hypoxia, thereby impairing cardiac function. 
 
Effect of hypoxia on cardiac function and metabolism in PPARα-/-mice fed a high fat diet 
In order to test whether high fat feeding was operating via an alternative mechanism to PPARα regulation, 
PPARα-/- mice were fed a high fat diet, and housed in either normoxia or hypoxia.  High fat feeding had no effect 
on body weight or LV mass compared to chow fed PPARα-/- mice (Table S1).  Cardiac PPARα mRNA levels 
were unaffected by high fat feeding, and PPARδ mRNA, and PPARȖ and RXR proteins were unaltered 
compared to chow fed PPARα-/- mice, with no effect of hypoxia (Figure 6A). Cardiac UCP3, MTE-1, PDK 4 and 
MCAD proteins were unaltered in PPARα-/- mice fed a high fat diet compared to a chow diet, again unaffected 
by chronic hypoxia (Figure 6B). Cardiac metabolism in PPARα-/- mice was also unaltered by either high fat 
feeding, or the addition of hypoxia (Figure 6C,D).  Cardiac output in PPARα-/- mice fed a high fat diet was 29% 
lower than chow fed PPARα-/- mice (p <0.01), and 18% lower with hypoxia (p < 0.01), similar to chow fed 
PPARα-/- mice exposed to chronic hypoxia (Figure 6E). Cardiac index was 29% lower in PPARα-/- mice fed a 
high fat diet vs chow, with no effect of hypoxia (p < 0.01). Ejection fraction was 6% lower in high fat fed 
PPARα-/- mice, and unaltered by hypoxia (p < 0.05).  Therefore PPARα ablation nullified the metabolic 
flexibility seen in healthy mice fed a high fat diet, resulting in impaired cardiac function and unaltered by 
hypoxia. 
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Effect of hypoxia and a high fat diet on whole body physiology and PPARα-regulated proteins in skeletal 
muscle 
In order to investigate the weight loss observed in wild-type hypoxic mice fed a high-fat diet (Table S1), energy 
intake was measured during the 3wk protocol.  Food consumption was not affected by hypoxia, or by the high-
fat diet (Figure 7A).  However, due to higher calorific value, there was a 28% (p<0.05) higher energy intake on 
high fat diet, which again was unaffected by hypoxia.  Cardiac levels of UCP3 and MTE-1 were elevated by 
high fat feeding (Figure 4B), suggesting that skeletal muscle uncoupling proteins responded to the high fat diet 
in a similar manner, thereby contributing to body weight loss in hypoxia.  UCP3 protein levels in skeletal 
(gastrocnemius) muscle were 26% (p<0.05) lower after 3wks of hypoxia (Figures 7B and S5), a similar response 
to that in cardiac muscle (Figure 3B).  As found in cardiac muscle, UCP3 levels in skeletal muscle increased 
with high fat feeding compared to chow-fed controls (p<0.001), and were not altered by hypoxia.  Skeletal 
muscle MTE-1 protein levels showed identical responses to those of UCP3, being 34% (p<0.05) lower in 
hypoxic chow-fed mice, and 71% (p<0.001) higher after high fat feeding with/without hypoxia.  PDK4 protein 
levels increased by 55% (p<0.01) during high fat feeding, which again prevented the adaptive responses to 
hypoxia. 
 
Effect of hypoxia or direct HIF activation on HL-1 cardiac cells 
Having established that adaptation to cardiac hypoxia was regulated by PPARα, we used confluent, beating HL-
1 cardiac cells to investigate whether such adaptations were directly linked to the HIF system.  Cells were 
exposed to hypoxia (2% O2) for 24 h, or the HIF system was chemically induced using 24 h incubation with the 
selective prolyl hydroxylase inhibitor, IOX3.(33)  Hypoxia caused a 5-fold increase in HIF-1α (p<0.001) and a 
72% increase in HIF-2α (p<0.05) protein levels (Figures 8A and S5).  IOX3 was a more potent activator of the 
HIF system than hypoxia, with a 9-fold increase in HIF-1α (p<0.001) and doubling of HIF-2α (p<0.01) protein 
levels after 24 h incubation.  Under HIF-1α control, VEGF mRNA increased by 37% (p<0.05) in hypoxia and 
59% (p<0.001) with IOX3.  PDK1  protein levels increased 34% in hypoxia (p<0.05) and 86% with IOX3 
treatment (p<0.01). GLUT-1 protein levels increased by 48% (p<0.02) with hypoxia and 3-fold (p<0.01) with 
IOX3. 
Hypoxia decreased PPARα mRNA by 23% (p<0.01) in HL-1 cells (Figure 8B), similar to that caused by in vivo 
hypoxia in the intact heart.  IOX3 produced a similar, 25% decrease in PPARα mRNA (p<0.001).  PPARδ 
mRNA levels were unaffected by hypoxia or IOX3.  PPARȖ mRNA levels were not altered by hypoxia, but were 
doubled (p<0.001) after IOX3 incubation.   
In cultured cardiac cells, PPAR controlled mRNA expression was altered by hypoxia in a similar manner as the 
respective protein in the in vivo hypoxic heart (Figure 8C).  UCP3 levels were lowered by 27% (p<0.01) by 
hypoxia, but were not altered by IOX3.  MCAD levels were 31% (p<0.001) lower after hypoxia and 17% 
(p<0.01) lower after IOX3.  PDK4 levels were unaffected by either hypoxia or IOX3. 
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Discussion 
In this study, we have demonstrated that normobaric hypoxia in mice decreased myocardial PPAR expression, 
fatty acid oxidation and mitochondrial UCP3, and increased carbohydrate metabolism; such changes allowed 
normoxic ATP concentrations and contractile function to be maintained.  Genetic ablation of PPARα in mice 
caused metabolic changes in the normoxic mouse heart that were already at the extreme of hypoxic adaptation 
and therefore could not be altered by hypoxia.  A high fat diet increased mouse heart PPARα expression and 
prevented PPARα down-regulation by hypoxia.  Thus, with high fat feeding, the cardiac proteins under PPARα 
control, UCP3, MTE-1, PDK4 and MCAD, and fatty acid oxidation, increased, while GLUT4 levels and 
glycolysis decreased: metabolic changes that remained in hypoxia.  Consequently, the high fat diet plus 3 weeks 
exposure to hypoxia significantly decreased myocardial ATP concentrations, cardiac index and ejection fraction.  
To our knowledge, this is the first time that an increase in a dietary constituent, fat, has been shown to cause 
myocardial dysfunction in hypoxia, a finding that may have implications for altitude exposure(34) or heart 
failure (in which similar metabolic changes, the “fetal gene program”, occur).(1, 28, 35, 36)  However, the 
human diet typically contains ~30% fat and probably seldom the 7.5% or 55% fat used in the mouse diets. 
PPAR down-regulation and substrate switching is essential for the maintenance of contractile function of the 
hypertrophied heart(37) and there have been reports of decreased PPAR expression in the heart following in 
vivo hypoxia.24, 26-28  In our mice, PPARα appeared to be the sole PPAR isoform involved in the myocardial 
metabolic changes, as neither PPARδ nor PPARȖ levels changed.  In agreement with findings in human skeletal 
muscle at altitude,(38) there were no changes in PGC1 nor were cardiac RXR protein levels decreased 
significantly by hypoxia.  In cultured cardiomyocytes, however, others have demonstrated decreased hypoxia-
induced PPARα/RXR DNA binding due to decreased RXR(39) or increased HIF1 levels.  PPARα has been 
linked to hypoxic adaptation in high altitude tolerant humans(19) and simulated hypoxia, using cobalt chloride to 
inhibit prolyl hydroxylases(40), decreased PPARα mRNA(9), suggesting regulation of PPARα via the HIF 
system.  Certainly, in beating cardiomyocytes, we found that either hypoxia or prolyl hydroxylase inhibition 
increased HIF1 and HIF2whilst decreasing PPAR MCAD and UCP3 expression, decreased UCP3 levels 
being a beneficial adaptation to hypoxia.(41) 
Yet studies of the HIF complex in transgenic(23) or knock-out mouse hearts(21, 22, 26) or skeletal muscle(25) 
have yielded apparently conflicting (and confusing) results, in that decreased HIF1,(21) HIF1 or 
HIF2 or increased HIF1 or HIF2 are reported to increase,(21, 23, 25) or not alter,(22) PPAR 
or decrease PPAR expression with increased(21) or no change(25) in fatty acid oxidation.  Of course, these 
are not studies on the metabolic effects of hypoxia, but on the contribution of individual constituents of the HIF 
pathway to changes in metabolism via the PPAR transcription factors.  So, both increased(25) or decreased(21) 
HIF2 increased PPAR expression, whereas decreased HIF1 increased either PPAR or PPAR 
expression.  It is difficult to compare such studies as few, and rarely the same, measures of myocardial 
metabolism or function have been made and seldom using the same techniques. 
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However, most studies reported the deposition of lipids in the heart(21-23, 26) or cardiomyocytes(24) whether 
HIF1 was increased(24, 26) or decreased.(22, 23)  We also found increased triacylglycerol in all hypoxic 
mouse hearts, whether or not PPAR levels and fatty acid oxidation were increased or decreased and unrelated 
to the effects of hypoxia on contractile function.  Indeed, both the high fat-fed and the PPAR-/- mouse hearts 
had high triacylglycerol levels in normoxia that were unaltered by hypoxia, suggesting that more fatty acids were 
taken up than could be oxidised and that lipid deposits per se do not cause cardiac injury. 
 
Carbohydrate metabolism was increased with hypoxia, but high fat feeding prevented this potentially adaptive 
mechanism.  GLUT4 was downregulated with activation of PPARα via high fat feeding and was unaltered by 
chronic hypoxia.  Consistent with this finding, PPARα overexpression is known to repress GLUT4 mRNA (42), 
and we have shown that cardiac GLUT4 content is reduced in obesity (43). Lower GLUT-4 levels may have 
contributed to cardiac dysfunction when hypoxia was combined with a high fat diet, preventing increased 
carbohydrate metabolism and resulting in lower cardiac ATP concentrations in hypoxic mice. 
 
Ventricular mass was lower in chronically hypoxic mice, resulting in cardiac hypotrophy. This reflects human 
studies of altitude exposure in sea-level natives (12). The stimulus for such reduction in LV mass, in the absence 
of loss of body weight may be a requirement to improve oxygen diffusion distances in tissue with a sustained, 
high oxygen demand (44).  The molecular mechanisms associated with such loss of cardiac muscle are 
incompletely understood, but may involve a reversal of the hypertrophic mechanisms associated with 
physiological hypertrophy (45).  In hypoxic mice fed a high fat diet, whilst absolute left ventricular mass fell in 
hypoxia, cardiac hypotrophy was not evident, as hypoxic high fat fed animals also lost body weight.  The 
molecular mechanisms for this weight loss is unclear - however all groups of PPARα-/- mice in this study were 
smaller than wild type littermates, which potentially implicates PPARα in the regulation of body weight. 
 
Not only did hypoxia decrease PPARα mRNA levels and PPARα downstream targets, UCP3, MTE-1 and 
MCAD protein levels in heart, but also in skeletal muscle.  In contrast to the increased PPAR observed in 
skeletal muscle in the PHD1-deficient mouse,(25) the decrease in PPAR expression is in agreement with 
findings in human skeletal muscle at altitude in which UCP3 levels and ȕ-hydroxyacyl-CoA dehydrogenase, a ȕ-
oxidation enzyme and PPARα target, were downregulated.(38)  The adaptation to hypoxia via changes in 
PPARα expression, observed here in heart and skeletal muscle, may be relevant to other organs that have high 
PPARα expression, such as liver, kidney and intestine.(46)  As in the heart, we found that the high fat diet 
increased (and prevented any hypoxia-induced decrease in) UCP3, MTE-1 and PDK4 in mouse skeletal muscle.  
Although the high-fat fed mice consumed 28% more calories than those on the chow diet, they did not gain 
weight, possibly owing to energy wastage via increased mitochondrial uncoupling.(3) 
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The normobaric hypoxia-induced decrease in cardiac PCr in our mice has been shown in human heart as a 
decrease in PCr/ATP, measured using in vivo MRS: in low-landers following a trek to Mt Everest Base 
Camp,(12) and in Sherpa volunteers, even after 4 weeks of de-acclimation at low altitudes.(11)  The decreased 
cardiac PCr/ATP in the Sherpa hearts was attributed to the requirement for a higher [ADP]free, to be closer to the 
Km of 110 M(47) for ADP-requiring pyruvate kinase activity in glycolysis, reflecting the elevated contribution 
of carbohydrate to myocardial energy needs.(7, 11)  Such a mechanism may be related to a decrease in PPAR 
levels via high altitude adaptation of the PPAR gene in Tibetans(19) and could explain why the highest free 
ADP concentrations occurred in the highly glycolytic PPAR-/- mouse hearts in both normoxia and hypoxia.  
However, a genetic adaptation cannot explain the 18% decrease in myocardial PCr/ATP and diastolic 
dysfunction in human lowlanders after a trek to Mt Everest,(12) which may have been exacerbated by the 
hypobaria and due to the requirement for increased [ADP]free plus the insulin resistance and elevated epinephrine 
observed in the same cohort.(48) 
The cytosolic free ADP concentration is a key metabolite controlling oxidative phosphorylation,(4) so it is 
possible that the decrease in PCr in the hypoxic mouse hearts was due to the need for higher [ADP]free to 
stimulate mitochondrial respiration and to increase glycolytic flux.  The requirement for oxygen would have 
been decreased in the hypoxic hearts by the decrease in fatty acid oxidation and mitochondrial uncoupling, with 
increased flux through PDH and thereby increased glucose oxidation, all of which allowed the ATP 
concentrations and contractile function to remain at normoxic levels. 
In the mice fed a high fat diet in normoxia, myocardial PCr decreased with no loss of total creatine, in order to 
maintain normal ATP levels and cardiac function despite the increased oxygen required for fatty acid oxidation 
and increased oxygen wastage via mitochondrial uncoupling.  Such changes with high fat diets have been 
observed in human(49) and rat hearts, associated with decreased efficiency.(3)  However, when the oxygen 
supply was restricted, the combination of greater oxygen requirement for fatty acid oxidation, plus oxygen 
wastage via increased mitochondrial UCP3 proteins, significantly decreased ATP, cardiac index and ejection 
fraction.  Similarly, mice with a cardiac-specific ARNT ablation had increased PPAR expression and fatty acid 
oxidation with decreased ejection fraction.(21) 
The metabolic changes caused by hypoxia in wild-type mouse hearts were found to have already occurred in 
normoxic PPARα-/- mouse hearts, and did not change further with hypoxia.  PPARα-/- mouse hearts maintained 
normal cardiac index and ejection fractions in hypoxia owing to high [ADP]free, high glycolytic flux, low PDK4 
(suggesting increased PDH flux and glucose oxidation), low fatty acid oxidation and low mitochondrial UCP3 
and MTE-1 levels, all of which would have resulted in the most efficient use of any available oxygen.  Thus 
metabolism in the normoxic PPAR-/- mouse heart may be viewed as at the extreme of hypoxic adaptation, 
which increases resistance to ischemia,(50, 51) but may not support a high workload(52) with greater 
hypertrophy and functional impairment following aortic constriction.(53)  It is possible that the PPAR-/- mouse 
hearts may have had decreased ejection fractions, in addition to the lower cardiac output and higher heart rates, 
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with a longer duration of hypoxia.  Because metabolism in PPAR-/- mouse hearts was at the limit of hypoxic 
adaptation during normoxia, with no response to hypoxia, the use of PPAR-/- mice to validate PPAR as a HIF 
target is questionable.  For example, knockout mice with decreased HIF2 (HIF1-/-)(21), increased HIF2 
(Phd1-/-)(25) and decreased HIF1 (Tg Nox-/-)(22) had their metabolic phenotypes reversed in a double knockout 
made by crossing with PPAR-/- mice. 
In summary, we propose that decreased myocardial PPARα expression is central to the metabolic changes 
required to maintain contractile function in hypoxia.  A high fat diet increased PPARα expression, fatty acid 
oxidation and mitochondrial uncoupling protein levels - changes that were tolerated in normoxia, but decreased 
ATP and impaired cardiac function in hypoxia.  Finally, the metabolic changes in normoxic PPAR-/- mouse 
heart can be viewed as at the extreme of hypoxic metabolic adaptation, in that they have no metabolic response 
to hypoxia. 
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Figure 3. Effects of 3 weeks of hypoxia on cardiac PPAR and PPAR mRNA, plus PPAR, 
RXR and PGC-1 proteins (A), PPAR-controlled proteins (B), myocardial 
carbohydrate and lipid metabolism (C and D), 31P MR spectra and high energy 
phosphate metabolism (E) and in vivo cardiac function (F) in wild-type mice fed a 
(7.5% fat) chow diet, min n=6.  * p<0.05 vs. normoxic chow-fed control, min n=6. 
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Figure 4. Effects of a high (55%) fat diet plus 3 weeks of hypoxia in wild-type mice on cardiac 
PPAR and PPAR mRNA, plus PPAR, RXR and PGC-1 proteins (A), PPAR 
controlled proteins (B), myocardial carbohydrate and lipid metabolism (C and D), 31P MR 
spectra and high energy phosphate metabolism (E) and in vivo cardiac function (F), min 
n=6.  Data in gray shows hypoxic response of chow-fed wild-type mice for comparison.  * 
p<0.05 vs. normoxic chow-fed control, † p<0.05 vs. normoxic high fat-fed control. 
 
 Figure 5. Effects of 3 weeks of hypoxia in PPARα-/- mice, fed a chow (7.5% fat) diet, on cardiac 
PPAR and PPAR mRNA, plus PPAR, RXR and PGC-1 proteins (A), PPAR 
controlled proteins (B), myocardial carbohydrate and lipid metabolism (C and D), 31P 
MR spectra and high energy phosphate metabolism (E) and in vivo cardiac function (F), 
min n=6.  Data in gray shows the hypoxic response of chow-fed wild-type mice for 
comparison.  * p<0.05 vs normoxic chow-fed control, ‡ p<0.05 vs. normoxic PPARα-/- 
chow-fed. 
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Figure 6.  Effects of 3 weeks of hypoxia on PPARα-/- mice, fed a high fat (55% fat) diet, on cardiac 
PPARα mRNA, plus PPARγ and RXR proteins (A), PPARα controlled proteins (B), 
myocardial carbohydrate and lipid metabolism (C and D) and in vivo cardiac function (F), 
min n=6. Data in gray shows the hypoxic response of chow-fed pparα-/- mice for 
comparison. * p < 0.05 vs chow fed control, ‡ p < 0.05 vs chow fed PPARα-/-. 
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Figure 7. Effect of 3 weeks of hypoxia on energy intake (A, n=4), 
and skeletal muscle proteins (B, n=6), under PPARα 
control in wild-type mice fed chow (7.5% fat) or a high 
(55%) fat diet. * p<0.05 vs. normoxic chow-fed control. 
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Figure 8. Effect of 24 h hypoxia or a PHD inhibitor, IOX3, 
on HL1 cardiomyocytes, n=4. * p<0.05 vs 
normoxic cells, † p<0.05 vs hypoxic cells. 
 
